3gt8 › Citations

Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment.

Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J
Cell 137 1293-307 (2009)
Cited: 363 times
EuropePMC logo PMID: 19563760

Abstract

Signaling by the epidermal growth factor receptor requires an allosteric interaction between the kinase domains of two receptors, whereby one activates the other. We show that the intracellular juxtamembrane segment of the receptor, known to potentiate kinase activity, is able to dimerize the kinase domains. The C-terminal half of the juxtamembrane segment latches the activated kinase domain to the activator, and the N-terminal half of this segment further potentiates dimerization, most likely by forming an antiparallel helical dimer that engages the transmembrane helices of the activated receptor. Our data are consistent with a mechanism in which the extracellular domains block the intrinsic ability of the transmembrane and cytoplasmic domains to dimerize and activate, with ligand binding releasing this block. The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation.

Reviews - 3gt8 mentioned but not cited (6)

  1. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J. Mol Cell 42 9-22 (2011)
  2. Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Truong TH, Carroll KS. Biochemistry 51 9954-9965 (2012)
  3. Redox regulation of protein kinases. Truong TH, Carroll KS. Crit Rev Biochem Mol Biol 48 332-356 (2013)
  4. Redox-dependent regulation of epidermal growth factor receptor signaling. Heppner DE, van der Vliet A. Redox Biol 8 24-27 (2016)
  5. A Brief History of Single-Particle Tracking of the Epidermal Growth Factor Receptor. Clarke DT, Martin-Fernandez ML. Methods Protoc 2 (2019)
  6. Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs. Pinet L, Assrir N, van Heijenoort C. Biomolecules 11 1690 (2021)

Articles - 3gt8 mentioned but not cited (22)

  1. Molecular mechanisms of ubiquitin-dependent membrane traffic. Hurley JH, Stenmark H. Annu Rev Biophys 40 119-142 (2011)
  2. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Biochem J 448 417-423 (2012)
  3. Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. Dixit A, Verkhivker GM. PLoS Comput Biol 7 e1002179 (2011)
  4. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM. Clin Cancer Res 25 3341-3351 (2019)
  5. Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. Kovacs E, Das R, Wang Q, Collier TS, Cantor A, Huang Y, Wong K, Mirza A, Barros T, Grob P, Jura N, Bose R, Kuriyan J. Mol Cell Biol 35 3083-3102 (2015)
  6. ProKinO: a unified resource for mining the cancer kinome. McSkimming DI, Dastgheib S, Talevich E, Narayanan A, Katiyar S, Taylor SS, Kochut K, Kannan N. Hum Mutat 36 175-186 (2015)
  7. Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions. James KA, Verkhivker GM. PLoS One 9 e113488 (2014)
  8. The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers. Zanetti-Domingues LC, Korovesis D, Needham SR, Tynan CJ, Sagawa S, Roberts SK, Kuzmanic A, Ortiz-Zapater E, Jain P, Roovers RC, Lajevardipour A, van Bergen En Henegouwen PMP, Santis G, Clayton AHA, Clarke DT, Gervasio FL, Shan Y, Shaw DE, Rolfe DJ, Parker PJ, Martin-Fernandez ML. Nat Commun 9 4325 (2018)
  9. Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface. Claus J, Patel G, Autore F, Colomba A, Weitsman G, Soliman TN, Roberts S, Zanetti-Domingues LC, Hirsch M, Collu F, George R, Ortiz-Zapater E, Barber PR, Vojnovic B, Yarden Y, Martin-Fernandez ML, Cameron A, Fraternali F, Ng T, Parker PJ. Elife 7 (2018)
  10. Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins. White KA, Ruiz DG, Szpiech ZA, Strauli NB, Hernandez RD, Jacobson MP, Barber DL. Sci Signal 10 (2017)
  11. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Hanker AB, Brown BP, Meiler J, Marín A, Jayanthan HS, Ye D, Lin CC, Akamatsu H, Lee KM, Chatterjee S, Sudhan DR, Servetto A, Brewer MR, Koch JP, Sheehan JH, He J, Lalani AS, Arteaga CL. Cancer Cell 39 1099-1114.e8 (2021)
  12. EGFR: tale of the C-terminal tail. Gajiwala KS. Protein Sci 22 995-999 (2013)
  13. Co-conserved features associated with cis regulation of ErbB tyrosine kinases. Mirza A, Mustafa M, Talevich E, Kannan N. PLoS One 5 e14310 (2010)
  14. Anchor-based classification and type-C inhibitors for tyrosine kinases. Hsu KC, Sung TY, Lin CT, Chiu YY, Hsu JT, Hung HC, Sun CM, Barve I, Chen WL, Huang WC, Huang CT, Chen CH, Yang JM. Sci Rep 5 10938 (2015)
  15. Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation. Yang KS, Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. J Biol Chem 285 24014-24022 (2010)
  16. Pockets as structural descriptors of EGFR kinase conformations. Hasenahuer MA, Barletta GP, Fernandez-Alberti S, Parisi G, Fornasari MS. PLoS One 12 e0189147 (2017)
  17. Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors. Sun XQ, Chen L, Li YZ, Li WH, Liu GX, Tu YQ, Tang Y. Acta Pharmacol Sin 35 301-310 (2014)
  18. Statistical analysis of EGFR structures' performance in virtual screening. Li Y, Li X, Dong Z. J Comput Aided Mol Des 29 1045-1055 (2015)
  19. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Cell Rep 38 110291 (2022)
  20. A driving test for oncogenic mutations. Heppner DE, Beyett TS, Eck MJ. J Biol Chem 294 9390-9391 (2019)
  21. Allosteric activation of preformed EGF receptor dimers by a single ligand binding event. Purba ER, Saita EI, Akhouri RR, Öfverstedt LG, Wilken G, Skoglund U, Maruyama IN. Front Endocrinol (Lausanne) 13 1042787 (2022)
  22. Ligand-induced transmembrane conformational coupling in monomeric EGFR. Srinivasan S, Regmi R, Lin X, Dreyer CA, Chen X, Quinn SD, He W, Coleman MA, Carraway KL, Zhang B, Schlau-Cohen GS. Nat Commun 13 3709 (2022)


Reviews citing this publication (87)

  1. Cell signaling by receptor tyrosine kinases. Lemmon MA, Schlessinger J. Cell 141 1117-1134 (2010)
  2. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R. Pharmacol Res 79 34-74 (2014)
  3. The ERBB network: at last, cancer therapy meets systems biology. Yarden Y, Pines G. Nat Rev Cancer 12 553-563 (2012)
  4. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Wee P, Wang Z. Cancers (Basel) 9 (2017)
  5. The structural basis for control of eukaryotic protein kinases. Endicott JA, Noble ME, Johnson LN. Annu Rev Biochem 81 587-613 (2012)
  6. Roles for growth factors in cancer progression. Witsch E, Sela M, Yarden Y. Physiology (Bethesda) 25 85-101 (2010)
  7. Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes. Pelay-Gimeno M, Glas A, Koch O, Grossmann TN. Angew Chem Int Ed Engl 54 8896-8927 (2015)
  8. The EGFR family: not so prototypical receptor tyrosine kinases. Lemmon MA, Schlessinger J, Ferguson KM. Cold Spring Harb Perspect Biol 6 a020768 (2014)
  9. Spatial regulation of receptor tyrosine kinases in development and cancer. Casaletto JB, McClatchey AI. Nat Rev Cancer 12 387-400 (2012)
  10. Discoidin domain receptor functions in physiological and pathological conditions. Leitinger B. Int Rev Cell Mol Biol 310 39-87 (2014)
  11. The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer. Berchtold MW, Villalobo A. Biochim Biophys Acta 1843 398-435 (2014)
  12. Receptor tyrosine kinases: legacy of the first two decades. Schlessinger J. Cold Spring Harb Perspect Biol 6 (2014)
  13. A structural perspective on the regulation of the epidermal growth factor receptor. Kovacs E, Zorn JA, Huang Y, Barros T, Kuriyan J. Annu Rev Biochem 84 739-764 (2015)
  14. Mechanisms of receptor tyrosine kinase activation in cancer. Du Z, Lovly CM. Mol Cancer 17 58 (2018)
  15. EGFR-mutated lung cancer: a paradigm of molecular oncology. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. Oncotarget 1 497-514 (2010)
  16. Pseudokinases-remnants of evolution or key allosteric regulators? Zeqiraj E, van Aalten DM. Curr Opin Struct Biol 20 772-781 (2010)
  17. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. Pines G, Köstler WJ, Yarden Y. FEBS Lett 584 2699-2706 (2010)
  18. The molecular circuitry of brassinosteroid signaling. Belkhadir Y, Jaillais Y. New Phytol 206 522-540 (2015)
  19. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Eck MJ, Yun CH. Biochim Biophys Acta 1804 559-566 (2010)
  20. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Bae JH, Schlessinger J. Mol Cells 29 443-448 (2010)
  21. Tetraspanins Function as Regulators of Cellular Signaling. Termini CM, Gillette JM. Front Cell Dev Biol 5 34 (2017)
  22. Regulation of the catalytic activity of the EGF receptor. Endres NF, Engel K, Das R, Kovacs E, Kuriyan J. Curr Opin Struct Biol 21 777-784 (2011)
  23. Structural Basis for the Non-catalytic Functions of Protein Kinases. Kung JE, Jura N. Structure 24 7-24 (2016)
  24. Spatial and Temporal Regulation of Receptor Tyrosine Kinase Activation and Intracellular Signal Transduction. Bergeron JJ, Di Guglielmo GM, Dahan S, Dominguez M, Posner BI. Annu Rev Biochem 85 573-597 (2016)
  25. Lung injury and cancer: Mechanistic insights into ceramide and EGFR signaling under cigarette smoke. Goldkorn T, Filosto S. Am J Respir Cell Mol Biol 43 259-268 (2010)
  26. Collagen recognition and transmembrane signalling by discoidin domain receptors. Carafoli F, Hohenester E. Biochim Biophys Acta 1834 2187-2194 (2013)
  27. Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Li E, Hristova K. Cell Adh Migr 4 249-254 (2010)
  28. Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". Purba ER, Saita EI, Maruyama IN. Cells 6 (2017)
  29. Drug discovery and the human kinome: recent trends. Eglen R, Reisine T. Pharmacol Ther 130 144-156 (2011)
  30. Physical-chemical principles underlying RTK activation, and their implications for human disease. He L, Hristova K. Biochim Biophys Acta 1818 995-1005 (2012)
  31. Single-spanning transmembrane domains in cell growth and cell-cell interactions: More than meets the eye? Hubert P, Sawma P, Duneau JP, Khao J, Hénin J, Bagnard D, Sturgis J. Cell Adh Migr 4 313-324 (2010)
  32. Mechanisms of resistance to EGFR targeted therapies. Hrustanovic G, Lee BJ, Bivona TG. Cancer Biol Ther 14 304-314 (2013)
  33. The molecular basis of targeting protein kinases in cancer therapeutics. Tsai CJ, Nussinov R. Semin Cancer Biol 23 235-242 (2013)
  34. IL-1 and EGF regulate expression of genes important in inflammation and cancer. Kasza A. Cytokine 62 22-33 (2013)
  35. Proteus in the world of proteins: conformational changes in protein kinases. Rabiller M, Getlik M, Klüter S, Richters A, Tückmantel S, Simard JR, Rauh D. Arch Pharm (Weinheim) 343 193-206 (2010)
  36. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers. Nussinov R, Jang H, Tsai CJ, Cheng F. PLoS Comput Biol 15 e1006658 (2019)
  37. Signals and Receptors. Heldin CH, Lu B, Evans R, Gutkind JS. Cold Spring Harb Perspect Biol 8 a005900 (2016)
  38. Calmodulin-mediated regulation of the epidermal growth factor receptor. Sánchez-González P, Jellali K, Villalobo A. FEBS J 277 327-342 (2010)
  39. Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology. ElBanan MG, Amer AM, Zinn PO, Colen RR. Neuroimaging Clin N Am 25 141-153 (2015)
  40. Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cymer F, Schneider D. Cell Adh Migr 4 299-312 (2010)
  41. Putting together structures of epidermal growth factor receptors. Bessman NJ, Freed DM, Lemmon MA. Curr Opin Struct Biol 29 95-101 (2014)
  42. Epidermal growth factor: a new therapeutic target in glomerular disease. Flamant M, Bollée G, Hénique C, Tharaux PL. Nephrol Dial Transplant 27 1297-1304 (2012)
  43. Design principles underpinning the regulatory diversity of protein kinases. Oruganty K, Kannan N. Philos Trans R Soc Lond B Biol Sci 367 2529-2539 (2012)
  44. Assembly and activation of neurotrophic factor receptor complexes. Simi A, Ibáñez CF. Dev Neurobiol 70 323-331 (2010)
  45. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, Drouin R, Klonisch T. Eur J Pharmacol 625 23-30 (2009)
  46. Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia. Black LE, Longo JF, Carroll SL. Am J Pathol 189 1898-1912 (2019)
  47. Structure elucidation of dimeric transmembrane domains of bitopic proteins. Bocharov EV, Volynsky PE, Pavlov KV, Efremov RG, Arseniev AS. Cell Adh Migr 4 284-298 (2010)
  48. ERBB oncogene proteins as targets for monoclonal antibodies. Polanovski OL, Lebedenko EN, Deyev SM. Biochemistry (Mosc) 77 227-245 (2012)
  49. A view into the blind spot: solution NMR provides new insights into signal transduction across the lipid bilayer. Call ME, Chou JJ. Structure 18 1559-1569 (2010)
  50. Understanding single-pass transmembrane receptor signaling from a structural viewpoint-what are we missing? Bugge K, Lindorff-Larsen K, Kragelund BB. FEBS J 283 4424-4451 (2016)
  51. The RTK Interactome: Overview and Perspective on RTK Heterointeractions. Paul MD, Hristova K. Chem Rev 119 5881-5921 (2019)
  52. Receptor tyrosine kinase activation: From the ligand perspective. Trenker R, Jura N. Curr Opin Cell Biol 63 174-185 (2020)
  53. A tale of the epidermal growth factor receptor: The quest for structural resolution on cells. Tynan CJ, Lo Schiavo V, Zanetti-Domingues L, Needham SR, Roberts SK, Hirsch M, Rolfe DJ, Korovesis D, Clarke DT, Martin-Fernandez ML. Methods 95 86-93 (2016)
  54. Membrane receptor activation mechanisms and transmembrane peptide tools to elucidate them. Westerfield JM, Barrera FN. J Biol Chem 295 1792-1814 (2020)
  55. Asymmetric perturbations of signalling oligomers. Maksay G, Tőke O. Prog Biophys Mol Biol 114 153-169 (2014)
  56. Progress and prospects for structural studies of transmembrane interactions in single-spanning receptors. Trenker R, Call MJ, Call ME. Curr Opin Struct Biol 39 115-123 (2016)
  57. Receptor Guanylyl Cyclases in Sensory Processing. Maruyama IN. Front Endocrinol (Lausanne) 7 173 (2016)
  58. Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors. Valley CC, Lewis AK, Sachs JN. Biochim Biophys Acta Biomembr 1859 1398-1416 (2017)
  59. Afatinib and lung cancer. Jain P, Khanal R, Sharma A, Yan F, Sharma N. Expert Rev Anticancer Ther 14 1391-1406 (2014)
  60. Drug resistance in targeted cancer therapies with RAF inhibitors. Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Cancer Drug Resist 4 665-683 (2021)
  61. Juxtamembrane contribution to transmembrane signaling. Deng W, Li R. Biopolymers 104 317-322 (2015)
  62. Mechanisms of epidermal growth factor receptor signaling as characterized by patterned ligand activation and mutational analysis. Holowka D, Baird B. Biochim Biophys Acta Biomembr 1859 1430-1435 (2017)
  63. More than the sum of the parts: Toward full-length receptor tyrosine kinase structures. Diwanji D, Thaker T, Jura N. IUBMB Life 71 706-720 (2019)
  64. Structure-function relationships of ErbB RTKs in the plasma membrane of living cells. Arndt-Jovin DJ, Botelho MG, Jovin TM. Cold Spring Harb Perspect Biol 6 a008961 (2014)
  65. Regulation of Fibrotic Processes in the Liver by ADAM Proteases. Schmidt-Arras D, Rose-John S. Cells 8 (2019)
  66. The growing story of (ARABIDOPSIS) CRINKLY 4. Czyzewicz N, Nikonorova N, Meyer MR, Sandal P, Shah S, Vu LD, Gevaert K, Rao AG, De Smet I. J Exp Bot 67 4835-4847 (2016)
  67. Allosteric therapies for lung cancer. Ling Y, Jing M, Wang XD. Cancer Metastasis Rev 34 303-312 (2015)
  68. Effect of Membrane Composition on Receptor Association: Implications of Cancer Lipidomics on ErbB Receptors. Pawar AB, Sengupta D. J Membr Biol 251 359-368 (2018)
  69. Targeting kinase signaling pathways with constrained peptide scaffolds. Hanold LE, Fulton MD, Kennedy EJ. Pharmacol Ther 173 159-170 (2017)
  70. The Structural and Functional Diversity of Intrinsically Disordered Regions in Transmembrane Proteins. Appadurai R, Uversky VN, Srivastava A. J Membr Biol 252 273-292 (2019)
  71. Chemical synthesis of transmembrane peptide and its application for research on the transmembrane-juxtamembrane region of membrane protein. Sato T. Biopolymers 106 613-621 (2016)
  72. Recent progress in protein-protein interaction study for EGFR-targeted therapeutics. Feiner RC, Müller KM. Expert Rev Proteomics 13 817-832 (2016)
  73. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer. Martin-Fernandez ML, Clarke DT, Roberts SK, Zanetti-Domingues LC, Gervasio FL. Cells 8 (2019)
  74. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy. Rocca A, Andreis D, Fedeli A, Maltoni R, Sarti S, Cecconetto L, Pietri E, Schirone A, Bravaccini S, Serra P, Farolfi A, Amadori D. Expert Opin Drug Metab Toxicol 11 1647-1663 (2015)
  75. The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor. Boran AD. Biochem Soc Trans 40 195-199 (2012)
  76. EGFR-Targeted Photodynamic Therapy. Ulfo L, Costantini PE, Di Giosia M, Danielli A, Calvaresi M. Pharmaceutics 14 241 (2022)
  77. EGFR trafficking: effect of dimerization, dynamics, and mutation. Schultz DF, Billadeau DD, Jois SD. Front Oncol 13 1258371 (2023)
  78. Fucoidan's Molecular Targets: A Comprehensive Review of Its Unique and Multiple Targets Accounting for Promising Bioactivities Supported by In Silico Studies. Zayed A, Al-Saedi DA, Mensah EO, Kanwugu ON, Adadi P, Ulber R. Mar Drugs 22 29 (2023)
  79. Imaging strategies for receptor tyrosine kinase dimers in living cells. Zhang X, Yin J, Pan W, Li Y, Li N, Tang B. Anal Bioanal Chem 415 67-82 (2023)
  80. It Takes More than Two to Tango: Complex, Hierarchal, and Membrane-Modulated Interactions in the Regulation of Receptor Tyrosine Kinases. Kovacs T, Zakany F, Nagy P. Cancers (Basel) 14 944 (2022)
  81. RTK Inhibitors in Melanoma: From Bench to Bedside. Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. Cancers (Basel) 13 (2021)
  82. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis. Kadry YA, Lee JY, Witze ES. Open Biol 11 210033 (2021)
  83. Regulation of ErbB Receptors by the Ca2+ Sensor Protein Calmodulin in Cancer. Villalobo A. Biomedicines 11 661 (2023)
  84. Shifting the Focus of Signaling Abnormalities in Colon Cancer. Brown MA, Ried T. Cancers (Basel) 14 784 (2022)
  85. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Amelia T, Kartasasmita RE, Ohwada T, Tjahjono DH. Molecules 27 819 (2022)
  86. The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Li-Wan-Po A, Farndon PA, Kobayashi S, Mitsudomi T, Potter VA. Ann Pharmacother 45 263-275 (2011)
  87. The epidermal growth factor receptor in healthy pregnancy and preeclampsia. Clemente L, Bird IM. J Mol Endocrinol 70 e220105 (2023)

Articles citing this publication (248)

  1. Spatial control of EGF receptor activation by reversible dimerization on living cells. Chung I, Akita R, Vandlen R, Toomre D, Schlessinger J, Mellman I. Nature 464 783-787 (2010)
  2. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. Proc Natl Acad Sci U S A 107 7692-7697 (2010)
  3. Phosphorylation-dependent differential regulation of plant growth, cell death, and innate immunity by the regulatory receptor-like kinase BAK1. Schwessinger B, Roux M, Kadota Y, Ntoukakis V, Sklenar J, Jones A, Zipfel C. PLoS Genet 7 e1002046 (2011)
  4. Architecture and membrane interactions of the EGF receptor. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, Shaw DE. Cell 152 557-569 (2013)
  5. Conformational coupling across the plasma membrane in activation of the EGF receptor. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, Shan Y, Shaw DE, Wemmer DE, Groves JT, Kuriyan J. Cell 152 543-556 (2013)
  6. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Jura N, Shan Y, Cao X, Shaw DE, Kuriyan J. Proc Natl Acad Sci U S A 106 21608-21613 (2009)
  7. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, Jumper J, Kuriyan J, Shaw DE. Cell 149 860-870 (2012)
  8. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, Clark R, Fields C, Lewis Phillips GD, Prell RA, Danilenko DM, Franke Y, Stephan JP, Hwang J, Wu Y, Bostrom J, Sliwkowski MX, Fuh G, Eigenbrot C. Cancer Cell 20 472-486 (2011)
  9. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA. Cancer Res 72 3228-3237 (2012)
  10. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Liccardi G, Hartley JA, Hochhauser D. Cancer Res 71 1103-1114 (2011)
  11. Multiple mechanisms collectively regulate clathrin-mediated endocytosis of the epidermal growth factor receptor. Goh LK, Huang F, Kim W, Gygi S, Sorkin A. J Cell Biol 189 871-883 (2010)
  12. Regulation of human EGF receptor by lipids. Coskun Ü, Grzybek M, Drechsel D, Simons K. Proc Natl Acad Sci U S A 108 9044-9048 (2011)
  13. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. Cancer Cell 24 438-449 (2013)
  14. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Campbell MR, Amin D, Moasser MM. Clin Cancer Res 16 1373-1383 (2010)
  15. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Alvarado D, Klein DE, Lemmon MA. Cell 142 568-579 (2010)
  16. Cell membranes: the lipid perspective. Coskun U, Simons K. Structure 19 1543-1548 (2011)
  17. Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. Nagy P, Claus J, Jovin TM, Arndt-Jovin DJ. Proc Natl Acad Sci U S A 107 16524-16529 (2010)
  18. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Mi LZ, Lu C, Li Z, Nishida N, Walz T, Springer TA. Nat Struct Mol Biol 18 984-989 (2011)
  19. Crystal structures of the phosphorylated BRI1 kinase domain and implications for brassinosteroid signal initiation. Bojar D, Martinez J, Santiago J, Rybin V, Bayliss R, Hothorn M. Plant J 78 31-43 (2014)
  20. Crystallographic insight into collagen recognition by discoidin domain receptor 2. Carafoli F, Bihan D, Stathopoulos S, Konitsiotis AD, Kvansakul M, Farndale RW, Leitinger B, Hohenester E. Structure 17 1573-1581 (2009)
  21. EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR. Kaplan M, Narasimhan S, de Heus C, Mance D, van Doorn S, Houben K, Popov-Čeleketić D, Damman R, Katrukha EA, Jain P, Geerts WJC, Heck AJR, Folkers GE, Kapitein LC, Lemeer S, van Bergen En Henegouwen PMP, Baldus M. Cell 167 1241-1251.e11 (2016)
  22. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Gajiwala KS, Feng J, Ferre R, Ryan K, Brodsky O, Weinrich S, Kath JC, Stewart A. Structure 21 209-219 (2013)
  23. N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes. Kaszuba K, Grzybek M, Orłowski A, Danne R, Róg T, Simons K, Coskun Ü, Vattulainen I. Proc Natl Acad Sci U S A 112 4334-4339 (2015)
  24. Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Maruyama IN. Cells 3 304-330 (2014)
  25. Molecular basis for multimerization in the activation of the epidermal growth factor receptor. Huang Y, Bharill S, Karandur D, Peterson SM, Marita M, Shi X, Kaliszewski MJ, Smith AW, Isacoff EY, Kuriyan J. Elife 5 (2016)
  26. The FRET signatures of noninteracting proteins in membranes: simulations and experiments. King C, Sarabipour S, Byrne P, Leahy DJ, Hristova K. Biophys J 106 1309-1317 (2014)
  27. Cigarette smoke induces aberrant EGF receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Filosto S, Becker CR, Goldkorn T. Mol Cancer Ther 11 795-804 (2012)
  28. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Sci Signal 7 ra114 (2014)
  29. Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation. Macdonald-Obermann JL, Pike LJ. J Biol Chem 289 26178-26188 (2014)
  30. Characterization of the CaMKKβ-AMPK signaling complex. Green MF, Anderson KA, Means AR. Cell Signal 23 2005-2012 (2011)
  31. How IGF-1 activates its receptor. Kavran JM, McCabe JM, Byrne PO, Connacher MK, Wang Z, Ramek A, Sarabipour S, Shan Y, Shaw DE, Hristova K, Cole PA, Leahy DJ. Elife 3 (2014)
  32. Mechanistic insights into the activation of oncogenic forms of EGF receptor. Wang Z, Longo PA, Tarrant MK, Kim K, Head S, Leahy DJ, Cole PA. Nat Struct Mol Biol 18 1388-1393 (2011)
  33. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Bill A, Gutierrez A, Kulkarni S, Kemp C, Bonenfant D, Voshol H, Duvvuri U, Gaither LA. Oncotarget 6 9173-9188 (2015)
  34. Cytohesins are cytoplasmic ErbB receptor activators. Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M. Cell 143 201-211 (2010)
  35. Ligand-induced EGF receptor oligomerization is kinase-dependent and enhances internalization. Hofman EG, Bader AN, Voortman J, van den Heuvel DJ, Sigismund S, Verkleij AJ, Gerritsen HC, van Bergen en Henegouwen PM. J Biol Chem 285 39481-39489 (2010)
  36. Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging. Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. Proc Natl Acad Sci U S A 109 137-142 (2012)
  37. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, Dutt A, Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M. Cancer Res 71 7587-7596 (2011)
  38. Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Wang Y, Gao J, Guo X, Tong T, Shi X, Li L, Qi M, Wang Y, Cai M, Jiang J, Xu C, Ji H, Wang H. Cell Res 24 959-976 (2014)
  39. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. Filosto S, Khan EM, Tognon E, Becker C, Ashfaq M, Ravid T, Goldkorn T. PLoS One 6 e23240 (2011)
  40. Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation. Michailidis IE, Rusinova R, Georgakopoulos A, Chen Y, Iyengar R, Robakis NK, Logothetis DE, Baki L. Pflugers Arch 461 387-397 (2011)
  41. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization. Chen L, Placone J, Novicky L, Hristova K. Sci Signal 3 ra86 (2010)
  42. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. Monsey J, Shen W, Schlesinger P, Bose R. J Biol Chem 285 7035-7044 (2010)
  43. Insights into EB1 structure and the role of its C-terminal domain for discriminating microtubule tips from the lattice. Buey RM, Mohan R, Leslie K, Walzthoeni T, Missimer JH, Menzel A, Bjelic S, Bargsten K, Grigoriev I, Smal I, Meijering E, Aebersold R, Akhmanova A, Steinmetz MO. Mol Biol Cell 22 2912-2923 (2011)
  44. Conformational Changes in the Epidermal Growth Factor Receptor: Role of the Transmembrane Domain Investigated by Coarse-Grained MetaDynamics Free Energy Calculations. Lelimousin M, Limongelli V, Sansom MS. J Am Chem Soc 138 10611-10622 (2016)
  45. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. Lu C, Mi LZ, Schürpf T, Walz T, Springer TA. J Biol Chem 287 38244-38253 (2012)
  46. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Pines G, Huang PH, Zwang Y, White FM, Yarden Y. Oncogene 29 5850-5860 (2010)
  47. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. Valley CC, Arndt-Jovin DJ, Karedla N, Steinkamp MP, Chizhik AI, Hlavacek WS, Wilson BS, Lidke KA, Lidke DS. Mol Biol Cell 26 4087-4099 (2015)
  48. Mechanistic insights into EGFR membrane clustering revealed by super-resolution imaging. Gao J, Wang Y, Cai M, Pan Y, Xu H, Jiang J, Ji H, Wang H. Nanoscale 7 2511-2519 (2015)
  49. Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Artim SC, Mendrola JM, Lemmon MA. Biochem J 448 213-220 (2012)
  50. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Bocharov EV, Lesovoy DM, Goncharuk SA, Goncharuk MV, Hristova K, Arseniev AS. Structure 21 2087-2093 (2013)
  51. Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach. Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, Clayton AH. Mol Biosyst 9 1849-1863 (2013)
  52. Bipartite tetracysteine display reveals allosteric control of ligand-specific EGFR activation. Scheck RA, Lowder MA, Appelbaum JS, Schepartz A. ACS Chem Biol 7 1367-1376 (2012)
  53. Allosteric communication across the native and mutated KIT receptor tyrosine kinase. Laine E, Auclair C, Tchertanov L. PLoS Comput Biol 8 e1002661 (2012)
  54. Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor. Bessman NJ, Bagchi A, Ferguson KM, Lemmon MA. Cell Rep 9 1306-1317 (2014)
  55. Kinase-mediated quasi-dimers of EGFR. Bublil EM, Pines G, Patel G, Fruhwirth G, Ng T, Yarden Y. FASEB J 24 4744-4755 (2010)
  56. Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis. Hopkins S, Linderoth E, Hantschel O, Suarez-Henriques P, Pilia G, Kendrick H, Smalley MJ, Superti-Furga G, Ferby I. Dev Cell 23 547-559 (2012)
  57. Time-resolved fluorescence spectroscopy measures clustering and mobility of a G protein-coupled receptor opsin in live cell membranes. Comar WD, Schubert SM, Jastrzebska B, Palczewski K, Smith AW. J Am Chem Soc 136 8342-8349 (2014)
  58. Interactions of the EGFR juxtamembrane domain with PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics simulations. Abd Halim KB, Koldsø H, Sansom MSP. Biochim Biophys Acta 1850 1017-1025 (2015)
  59. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations. Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S. Cancer Cell 34 792-806.e5 (2018)
  60. Transmembrane helix orientation influences membrane binding of the intracellular juxtamembrane domain in Neu receptor peptides. Matsushita C, Tamagaki H, Miyazawa Y, Aimoto S, Smith SO, Sato T. Proc Natl Acad Sci U S A 110 1646-1651 (2013)
  61. Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells. Capuani F, Conte A, Argenzio E, Marchetti L, Priami C, Polo S, Di Fiore PP, Sigismund S, Ciliberto A. Nat Commun 6 7999 (2015)
  62. Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. Kim Y, Li Z, Apetri M, Luo B, Settleman JE, Anderson KS. Biochemistry 51 5212-5222 (2012)
  63. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms. van Lengerich B, Agnew C, Puchner EM, Huang B, Jura N. Proc Natl Acad Sci U S A 114 E2836-E2845 (2017)
  64. FGFR3 unliganded dimer stabilization by the juxtamembrane domain. Sarabipour S, Hristova K. J Mol Biol 427 1705-1714 (2015)
  65. Lineage-specific co-evolution of the Egf receptor/ligand signaling system. Laisney JA, Braasch I, Walter RB, Meierjohann S, Schartl M. BMC Evol Biol 10 27 (2010)
  66. Oligomerization of DHHC protein S-acyltransferases. Lai J, Linder ME. J Biol Chem 288 22862-22870 (2013)
  67. Phosphorylated EGFR Dimers Are Not Sufficient to Activate Ras. Liang SI, van Lengerich B, Eichel K, Cha M, Patterson DM, Yoon TY, von Zastrow M, Jura N, Gartner ZJ. Cell Rep 22 2593-2600 (2018)
  68. Structural and functional characterization of alternative transmembrane domain conformations in VEGF receptor 2 activation. Manni S, Mineev KS, Usmanova D, Lyukmanova EN, Shulepko MA, Kirpichnikov MP, Winter J, Matkovic M, Deupi X, Arseniev AS, Ballmer-Hofer K. Structure 22 1077-1089 (2014)
  69. Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications. Sánchez-Martín M, Pandiella A. Int J Cancer 131 244-252 (2012)
  70. Evolutionary-guided de novo structure prediction of self-associated transmembrane helical proteins with near-atomic accuracy. Wang Y, Barth P. Nat Commun 6 7196 (2015)
  71. Inside-out Regulation of Ectodomain Cleavage of Cluster-of-Differentiation-44 (CD44) and of Neuregulin-1 Requires Substrate Dimerization. Hartmann M, Parra LM, Ruschel A, Lindner C, Morrison H, Herrlich A, Herrlich P. J Biol Chem 290 17041-17054 (2015)
  72. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? Tsai CJ, Nussinov R. Phys Chem Chem Phys 16 6332-6341 (2014)
  73. Conserved Lipid and Small-Molecule Modulation of COQ8 Reveals Regulation of the Ancient Kinase-like UbiB Family. Reidenbach AG, Kemmerer ZA, Aydin D, Jochem A, McDevitt MT, Hutchins PD, Stark JL, Stefely JA, Reddy T, Hebert AS, Wilkerson EM, Johnson IE, Bingman CA, Markley JL, Coon JJ, Dal Peraro M, Pagliarini DJ. Cell Chem Biol 25 154-165.e11 (2018)
  74. Dynamic conformational transitions of the EGF receptor in living mammalian cells determined by FRET and fluorescence lifetime imaging microscopy. Ziomkiewicz I, Loman A, Klement R, Fritsch C, Klymchenko AS, Bunt G, Jovin TM, Arndt-Jovin DJ. Cytometry A 83 794-805 (2013)
  75. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Sato K, Shin MS, Sakimura A, Zhou Y, Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I, Sakurai H. Cancer Sci 104 1315-1322 (2013)
  76. Single Particle Tracking Reveals that EGFR Signaling Activity Is Amplified in Clathrin-Coated Pits. Ibach J, Radon Y, Gelléri M, Sonntag MH, Brunsveld L, Bastiaens PI, Verveer PJ. PLoS One 10 e0143162 (2015)
  77. β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Balanis N, Yoshigi M, Wendt MK, Schiemann WP, Carlin CR. Mol Biol Cell 22 4288-4301 (2011)
  78. A helix heterodimer in a lipid bilayer: prediction of the structure of an integrin transmembrane domain via multiscale simulations. Kalli AC, Hall BA, Campbell ID, Sansom MS. Structure 19 1477-1484 (2011)
  79. Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging. Macdonald-Obermann JL, Adak S, Landgraf R, Piwnica-Worms D, Pike LJ. J Biol Chem 288 30773-30784 (2013)
  80. Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study. Mustafa M, Mirza A, Kannan N. Proteins 79 99-114 (2011)
  81. Ligand regulation of a constitutively dimeric EGF receptor. Freed DM, Alvarado D, Lemmon MA. Nat Commun 6 7380 (2015)
  82. Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. Li H, Panina S, Kaur A, Ruano MJ, Sánchez-González P, la Cour JM, Stephan A, Olesen UH, Berchtold MW, Villalobo A. J Biol Chem 287 3273-3281 (2012)
  83. The energy landscape analysis of cancer mutations in protein kinases. Dixit A, Verkhivker GM. PLoS One 6 e26071 (2011)
  84. Congress Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription. Brana I, Siu LL. Ann Oncol 23 Suppl 10 x178-85 (2012)
  85. Spatial structure and dimer--monomer equilibrium of the ErbB3 transmembrane domain in DPC micelles. Mineev KS, Khabibullina NF, Lyukmanova EN, Dolgikh DA, Kirpichnikov MP, Arseniev AS. Biochim Biophys Acta 1808 2081-2088 (2011)
  86. A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. Ryslik GA, Cheng Y, Cheung KH, Modis Y, Zhao H. BMC Bioinformatics 15 86 (2014)
  87. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways. Choi BK, Cai X, Yuan B, Huang Z, Fan X, Deng H, Zhang N, An Z. Protein Cell 3 781-789 (2012)
  88. Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases. Xu Q, Malecka KL, Fink L, Jordan EJ, Duffy E, Kolander S, Peterson JR, Dunbrack RL. Sci Signal 8 rs13 (2015)
  89. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. Shih AJ, Telesco SE, Choi SH, Lemmon MA, Radhakrishnan R. Biochem J 436 241-251 (2011)
  90. Overcoming resistance to HER2 inhibitors through state-specific kinase binding. Novotny CJ, Pollari S, Park JH, Lemmon MA, Shen W, Shokat KM. Nat Chem Biol 12 923-930 (2016)
  91. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Littlefield P, Moasser MM, Jura N. Chem Biol 21 453-458 (2014)
  92. Sulfiredoxin Promotes Colorectal Cancer Cell Invasion and Metastasis through a Novel Mechanism of Enhancing EGFR Signaling. Jiang H, Wu L, Chen J, Mishra M, Chawsheen HA, Zhu H, Wei Q. Mol Cancer Res 13 1554-1566 (2015)
  93. A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors. Del Piccolo N, Sarabipour S, Hristova K. J Biol Chem 292 1288-1301 (2017)
  94. Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM. Coban O, Zanetti-Dominguez LC, Matthews DR, Rolfe DJ, Weitsman G, Barber PR, Barbeau J, Devauges V, Kampmeier F, Winn M, Vojnovic B, Parker PJ, Lidke KA, Lidke DS, Ameer-Beg SM, Martin-Fernandez ML, Ng T. Biophys J 108 1013-1026 (2015)
  95. Evidence for extended YFP-EGFR dimers in the absence of ligand on the surface of living cells. Kozer N, Henderson C, Jackson JT, Nice EC, Burgess AW, Clayton AH. Phys Biol 8 066002 (2011)
  96. Inhibiting epidermal growth factor receptor at a distance. Sinclair JK, Denton EV, Schepartz A. J Am Chem Soc 136 11232-11235 (2014)
  97. Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase. Ruan Z, Kannan N. Biochemistry 54 4216-4225 (2015)
  98. Reorienting the Fab domains of trastuzumab results in potent HER2 activators. Scheer JM, Sandoval W, Elliott JM, Shao L, Luis E, Lewin-Koh SC, Schaefer G, Vandlen R. PLoS One 7 e51817 (2012)
  99. The NMR solution structure of human epidermal growth factor (hEGF) at physiological pH and its interactions with suramin. Huang HW, Mohan SK, Yu C. Biochem Biophys Res Commun 402 705-710 (2010)
  100. The tethering arm of the EGF receptor is required for negative cooperativity and signal transduction. Adak S, DeAndrade D, Pike LJ. J Biol Chem 286 1545-1555 (2011)
  101. A genetically encoded 19F NMR probe for tyrosine phosphorylation. Li F, Shi P, Li J, Yang F, Wang T, Zhang W, Gao F, Ding W, Li D, Li J, Xiong Y, Sun J, Gong W, Tian C, Wang J. Angew Chem Int Ed Engl 52 3958-3962 (2013)
  102. Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. Shih AJ, Telesco SE, Radhakrishnan R. Cancers (Basel) 3 1195-1231 (2011)
  103. Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling. Kluba M, Engelborghs Y, Hofkens J, Mizuno H. PLoS One 10 e0139971 (2015)
  104. Interactions of the EphA2 Kinase Domain with PIPs in Membranes: Implications for Receptor Function. Chavent M, Karia D, Kalli AC, Domański J, Duncan AL, Hedger G, Stansfeld PJ, Seiradake E, Jones EY, Sansom MSP. Structure 26 1025-1034.e2 (2018)
  105. RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements. Plaza-Menacho I, Barnouin K, Barry R, Borg A, Orme M, Chauhan R, Mouilleron S, Martínez-Torres RJ, Meier P, McDonald NQ. Cell Rep 17 3319-3332 (2016)
  106. Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Dixit A, Verkhivker GM. Comput Math Methods Med 2014 653487 (2014)
  107. The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding. Adak S, Yang KS, Macdonald-Obermann J, Pike LJ. J Biol Chem 286 45146-45155 (2011)
  108. A cancer-associated mutation in atypical protein kinase Cι occurs in a substrate-specific recruitment motif. Linch M, Sanz-Garcia M, Soriano E, Zhang Y, Riou P, Rosse C, Cameron A, Knowles P, Purkiss A, Kjaer S, McDonald NQ, Parker PJ. Sci Signal 6 ra82 (2013)
  109. Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence. He L, Hristova K. Sci Rep 2 854 (2012)
  110. Mutual cross-talk between fibronectin integrins and the EGF receptor: Molecular basis and biological significance. Balanis N, Carlin CR. Cell Logist 2 46-51 (2012)
  111. Yet another "active" pseudokinase, Erb3. Taylor SS, Kornev AP. Proc Natl Acad Sci U S A 107 8047-8048 (2010)
  112. Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation. Koland JG. PLoS Comput Biol 10 e1003435 (2014)
  113. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Riese DJ. Expert Opin Drug Discov 6 185-193 (2011)
  114. Computer-aided identification of EGFR tyrosine kinase inhibitors using ginsenosides from Panax ginseng. Sathishkumar N, Karpagam V, Sathiyamoorthy S, Woo MJ, Kim YJ, Yang DC. Comput Biol Med 43 786-797 (2013)
  115. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. Kawasaki Y, Sakimura A, Park CM, Tomaru R, Tanaka T, Ozawa T, Zhou Y, Narita K, Kishi H, Muraguchi A, Sakurai H. Sci Rep 6 31502 (2016)
  116. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation. Tanaka T, Zhou Y, Ozawa T, Okizono R, Banba A, Yamamura T, Oga E, Muraguchi A, Sakurai H. J Biol Chem 293 2288-2301 (2018)
  117. Ack1: activation and regulation by allostery. Gajiwala KS, Maegley K, Ferre R, He YA, Yu X. PLoS One 8 e53994 (2013)
  118. Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. Zhang H, Shen W, Rempel D, Monsey J, Vidavsky I, Gross ML, Bose R. Mol Cell Proteomics 10 M110.005678 (2011)
  119. Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y. Cancer Genomics Proteomics 14 83-91 (2017)
  120. Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry. Ward MD, Leahy DJ. J Biol Chem 290 1570-1579 (2015)
  121. Revisiting a controversy: The effect of EGF on EGFR dimer stability. Singh DR, King C, Salotto M, Hristova K. Biochim Biophys Acta Biomembr 1862 183015 (2020)
  122. Dynamic transition states of ErbB1 phosphorylation predicted by spatial stochastic modeling. Pryor MM, Low-Nam ST, Halász AM, Lidke DS, Wilson BS, Edwards JS. Biophys J 105 1533-1543 (2013)
  123. Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR). Sinclair JK, Schepartz A. Org Lett 16 4916-4919 (2014)
  124. Ligand-independent Tie2 dimers mediate kinase activity stimulated by high dose angiopoietin-1. Yamakawa D, Kidoya H, Sakimoto S, Jia W, Naito H, Takakura N. J Biol Chem 288 12469-12477 (2013)
  125. Modeling Cellular Noise Underlying Heterogeneous Cell Responses in the Epidermal Growth Factor Signaling Pathway. Iwamoto K, Shindo Y, Takahashi K. PLoS Comput Biol 12 e1005222 (2016)
  126. Bacterial Synthesis and Purification of Normal and Mutant Forms of Human FGFR3 Transmembrane Segment. Goncharuk SA, Goncharuk MV, Mayzel ML, Lesovoy DM, Chupin VV, Bocharov EV, Arseniev AS, Kirpichnikov MP. Acta Naturae 3 77-84 (2011)
  127. Comparative proteomic analysis of compartmentalised Ras signalling. Hernandez-Valladares M, Prior IA. Sci Rep 5 17307 (2015)
  128. Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M. PLoS One 6 e23396 (2011)
  129. Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation. Manni S, Kisko K, Schleier T, Missimer J, Ballmer-Hofer K. FASEB J 28 4914-4923 (2014)
  130. Mechanism of Allosteric Coupling into and through the Plasma Membrane by EGFR. Sinclair JKL, Walker AS, Doerner AE, Schepartz A. Cell Chem Biol 25 857-870.e7 (2018)
  131. Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation. Yamamoto K, Takahashi K, Shiozaki K, Yamaguchi K, Moriya S, Hosono M, Shima H, Miyagi T. PLoS One 10 e0120578 (2015)
  132. SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase. Knittle AM, Helkkula M, Johnson MS, Sundvall M, Elenius K. J Biol Chem 292 19890-19904 (2017)
  133. Sequence dependent lipid-mediated effects modulate the dimerization of ErbB2 and its associative mutants. Prasanna X, Praveen PJ, Sengupta D. Phys Chem Chem Phys 15 19031-19041 (2013)
  134. Thermodynamic and kinetic characterization of transmembrane helix association. Pawar AB, Deshpande SA, Gopal SM, Wassenaar TA, Athale CA, Sengupta D. Phys Chem Chem Phys 17 1390-1398 (2015)
  135. A lipophilicity-based energy function for membrane-protein modelling and design. Weinstein JY, Elazar A, Fleishman SJ. PLoS Comput Biol 15 e1007318 (2019)
  136. A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor. Boran AD, Seco J, Jayaraman V, Jayaraman G, Zhao S, Reddy S, Chen Y, Iyengar R. PLoS One 7 e49702 (2012)
  137. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors. Macdonald-Obermann JL, Pike LJ. J Biol Chem 293 13401-13414 (2018)
  138. Computational design of membrane proteins using RosettaMembrane. Duran AM, Meiler J. Protein Sci 27 341-355 (2018)
  139. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants. Park AK, Francis JM, Park WY, Park JO, Cho J. Oncotarget 6 8839-8850 (2015)
  140. Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites. Cantor AJ, Shah NH, Kuriyan J. Proc Natl Acad Sci U S A 115 E7303-E7312 (2018)
  141. Lipid-Protein Interplay in Dimerization of Juxtamembrane Domains of Epidermal Growth Factor Receptor. Maeda R, Sato T, Okamoto K, Yanagawa M, Sako Y. Biophys J 114 893-903 (2018)
  142. Mutations in the polybasic juxtamembrane sequence of both plasma membrane- and endoplasmic reticulum-localized epidermal growth factor receptors confer ligand-independent cell transformation. Bryant KL, Antonyak MA, Cerione RA, Baird B, Holowka D. J Biol Chem 288 34930-34942 (2013)
  143. Peptides Targeting EGF Block the EGF-EGFR Interaction. Guardiola S, Díaz-Lobo M, Seco J, García J, Nevola L, Giralt E. Chembiochem 17 702-711 (2016)
  144. Quantifying the Interaction between EGFR Dimers and Grb2 in Live Cells. Del Piccolo N, Hristova K. Biophys J 113 1353-1364 (2017)
  145. The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. Gajiwala KS, Grodsky N, Bolaños B, Feng J, Ferre R, Timofeevski S, Xu M, Murray BW, Johnson TW, Stewart A. J Biol Chem 292 15705-15716 (2017)
  146. A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. Xie X, Zhou W, Hu Y, Chen Y, Zhang H, Li Y. Cell Death Dis 9 379 (2018)
  147. Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor. Ogasawara M, Nakamura Y, Morikawa N, Nitanai H, Moriguchi S, Chiba R, Saito H, Ohta M, Tanita T, Sugai T, Maeyama K, Yamauchi K, Takaoka Y. Cancer Chemother Pharmacol 77 1019-1029 (2016)
  148. Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation. Fulton MD, Hanold LE, Ruan Z, Patel S, Beedle AM, Kannan N, Kennedy EJ. Bioorg Med Chem 26 1167-1173 (2018)
  149. Exploring the dynamics and interaction of a full ErbB2 receptor and Trastuzumab-Fab antibody in a lipid bilayer model using Martini coarse-grained force field. Franco-Gonzalez JF, Ramos J, Cruz VL, Martinez-Salazar J. J Comput Aided Mol Des 28 1093-1107 (2014)
  150. Inactive ERBB receptors cooperate with reactive oxygen species to suppress cancer progression. Hart MR, Su HY, Broka D, Goverdhan A, Schroeder JA. Mol Ther 21 1996-2007 (2013)
  151. Insights into molecular interactions between the juxtamembrane and kinase subdomains of the Arabidopsis Crinkly-4 receptor-like kinase. Meyer MR, Shah S, Rao AG. Arch Biochem Biophys 535 101-110 (2013)
  152. Orchestration of ErbB3 signaling through heterointeractions and homointeractions. McCabe Pryor M, Steinkamp MP, Halasz AM, Chen Y, Yang S, Smith MS, Zahoransky-Kohalmi G, Swift M, Xu XP, Hanein D, Volkmann N, Lidke DS, Edwards JS, Wilson BS. Mol Biol Cell 26 4109-4123 (2015)
  153. P130Cas attenuates epidermal growth factor (EGF) receptor internalization by modulating EGF-triggered dynamin phosphorylation. Kang YS, Kim W, Huh YH, Bae J, Kim JS, Song WK. PLoS One 6 e20125 (2011)
  154. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Du Z, Brown BP, Kim S, Ferguson D, Pavlick DC, Jayakumaran G, Benayed R, Gallant JN, Zhang YK, Yan Y, Red-Brewer M, Ali SM, Schrock AB, Zehir A, Ladanyi M, Smith AW, Meiler J, Lovly CM. Nat Commun 12 1382 (2021)
  155. The Dipole Potential Modifies the Clustering and Ligand Binding Affinity of ErbB Proteins and Their Signaling Efficiency. Kovács T, Batta G, Hajdu T, Szabó Á, Váradi T, Zákány F, Csomós I, Szöllősi J, Nagy P. Sci Rep 6 35850 (2016)
  156. The juxtamembrane linker in neutral sphingomyelinase-2 functions as an intramolecular allosteric switch that activates the enzyme. Shanbhogue P, Hoffmann RM, Airola MV, Maini R, Hamelin DJ, Garcia-Diaz M, Burke JE, Hannun YA. J Biol Chem 294 7488-7502 (2019)
  157. Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses. Moonrin N, Songtawee N, Rattanabunyong S, Chunsrivirot S, Mokmak W, Tongsima S, Choowongkomon K. BMC Bioinformatics 16 103 (2015)
  158. ERBB receptors in cancer: signaling from the inside. Arteaga CL. Breast Cancer Res 13 304 (2011)
  159. Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells. Pan T, Sun J, Zhou J, Fu Z, Hu Y, Zheng S, Zhang S. Oncol Lett 5 521-526 (2013)
  160. In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database. Sawatdichaikul O, Hannongbua S, Sangma C, Wolschann P, Choowongkomon K. J Mol Model 18 1241-1254 (2012)
  161. Induced heterodimerization and purification of two target proteins by a synthetic coiled-coil tag. Fernandez-Rodriguez J, Marlovits TC. Protein Sci 21 511-519 (2012)
  162. Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic. Gerhart J, Thévenin AF, Bloch E, King KE, Thévenin D. ACS Chem Biol 13 2623-2632 (2018)
  163. Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. Telesco SE, Shih A, Liu Y, Radhakrishnan R. Cancer Res J 4 1-35 (2011)
  164. Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. Frazier NM, Brand T, Gordan JD, Grandis J, Jura N. Oncogene 38 1936-1950 (2019)
  165. Probing the Heterogeneity of Protein Kinase Activation in Cells by Super-resolution Microscopy. Zhang R, Fruhwirth GO, Coban O, Barrett JE, Burgoyne T, Lee SH, Simonson PD, Baday M, Kholodenko BN, Futter CE, Ng T, Selvin PR. ACS Nano 11 249-257 (2017)
  166. Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. Liu L, Thaker TM, Freed DM, Frazier N, Malhotra K, Lemmon MA, Jura N. Structure 26 270-281.e4 (2018)
  167. Transphosphorylation of EGFR at Y845 plays an important role in its autophosphorylation and kinase activity. Song H, Huang L, Zhang M, Wang X, Song S, Yang L. Oncol Rep 31 2393-2398 (2014)
  168. A highly efficient peptide substrate for EGFR activates the kinase by inducing aggregation. Engel K, Sasaki T, Wang Q, Kuriyan J. Biochem J 453 337-344 (2013)
  169. An unbiased in vitro screen for activating epidermal growth factor receptor mutations. Chakroborty D, Kurppa KJ, Paatero I, Ojala VK, Koivu M, Tamirat MZ, Koivunen JP, Jänne PA, Johnson MS, Elo LL, Elenius K. J Biol Chem 294 9377-9389 (2019)
  170. Bacterial Phytochrome as a Scaffold for Engineering of Receptor Tyrosine Kinases Controlled with Near-Infrared Light. Leopold AV, Pletnev S, Verkhusha VV. J Mol Biol 432 3749-3760 (2020)
  171. Coaction of Electrostatic and Hydrophobic Interactions: Dynamic Constraints on Disordered TrkA Juxtamembrane Domain. Wang Z, Fan H, Hu X, Khamo J, Diao J, Zhang K, Pogorelov TV. J Phys Chem B 123 10709-10717 (2019)
  172. Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. Niggenaber J, Heyden L, Grabe T, Müller MP, Lategahn J, Rauh D. ACS Med Chem Lett 11 2484-2490 (2020)
  173. EGFR forms ligand-independent oligomers that are distinct from the active state. Byrne PO, Hristova K, Leahy DJ. J Biol Chem 295 13353-13362 (2020)
  174. Genomewide association mapping and pathway analysis of meat tenderness in Polled Nellore cattle. Castro LM, Rosa GJM, Lopes FB, Regitano LCA, Rosa AJM, Magnabosco CU. J Anim Sci 95 1945-1956 (2017)
  175. Growth factor and co-receptor release by structural regulation of substrate metalloprotease accessibility. Parra LM, Hartmann M, Schubach S, Ma J, Herrlich P, Herrlich A. Sci Rep 6 37464 (2016)
  176. Investigating extracellular in situ EGFR structure and conformational changes using FRET microscopy. Roberts SK, Tynan CJ, Winn M, Martin-Fernandez ML. Biochem Soc Trans 40 189-194 (2012)
  177. Ligand-Independent EGFR Activation by Anchorage-Stimulated Src Promotes Cancer Cell Proliferation and Cetuximab Resistance via ErbB3 Phosphorylation. Nozaki M, Yasui H, Ohnishi Y. Cancers (Basel) 11 (2019)
  178. Molecular dynamics of the asymmetric dimers of EGFR: simulations on the active and inactive conformations of the kinase domain. Songtawee N, Bevan DR, Choowongkomon K. J Mol Graph Model 58 16-29 (2015)
  179. Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor. Regmi R, Srinivasan S, Latham AP, Kukshal V, Cui W, Zhang B, Bose R, Schlau-Cohen GS. J Phys Chem Lett 11 10037-10044 (2020)
  180. Probing homodimer formation of epidermal growth factor receptor by selective crosslinking. Sun X, Dusserre-Bresson F, Baker B, Zhang A, Xu P, Fibbe C, Noren CJ, Corrêa IR, Xu MQ. Eur J Med Chem 88 34-41 (2014)
  181. S-Fms signalobody enhances myeloid cell growth and migration. Kawahara M, Hitomi A, Nagamune T. Biotechnol J 9 954-961 (2014)
  182. Single-Molecule Fluorescence Detection of the Epidermal Growth Factor Receptor in Membrane Discs. Quinn SD, Srinivasan S, Gordon JB, He W, Carraway KL, Coleman MA, Schlau-Cohen GS. Biochemistry 58 286-294 (2019)
  183. Split Intein-Mediated Protein Ligation for detecting protein-protein interactions and their inhibition. Yao Z, Aboualizadeh F, Kroll J, Akula I, Snider J, Lyakisheva A, Tang P, Kotlyar M, Jurisica I, Boxem M, Stagljar I. Nat Commun 11 2440 (2020)
  184. Structural basis of the transmembrane domain dimerization and rotation in the activation mechanism of the TRKA receptor by nerve growth factor. Franco ML, Nadezhdin KD, Goncharuk SA, Mineev KS, Arseniev AS, Vilar M. J Biol Chem 295 275-286 (2020)
  185. Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system. Scharadin TM, He W, Yiannakou Y, Tomilov AA, Saldana M, Cortopassi GA, Carraway KL, Coleman MA, Henderson PT. PLoS One 12 e0177761 (2017)
  186. TRAF4 binds to the juxtamembrane region of EGFR directly and promotes kinase activation. Cai G, Zhu L, Chen X, Sun K, Liu C, Sen GC, Stark GR, Qin J, Li X. Proc Natl Acad Sci U S A 115 11531-11536 (2018)
  187. A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor. Huang Y, Ognjenovic J, Karandur D, Miller K, Merk A, Subramaniam S, Kuriyan J. Elife 10 e73218 (2021)
  188. Bile acids target proteolipid nano-assemblies of EGFR and phosphatidic acid in the plasma membrane for stimulation of MAPK signaling. Liang H, Estes MK, Zhang H, Du G, Zhou Y. PLoS One 13 e0198983 (2018)
  189. Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells. Tanaka T, Ozawa T, Oga E, Muraguchi A, Sakurai H. Oncol Lett 15 9251-9256 (2018)
  190. Direct Profiling the Post-Translational Modification Codes of a Single Protein Immobilized on a Surface Using Cu-free Click Chemistry. Kim KL, Park KM, Murray J, Kim K, Ryu SH. ACS Cent Sci 4 614-623 (2018)
  191. Human epidermal growth factor receptor (HER1) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry. Martin-Fernandez ML. Biochem Soc Trans 40 184-188 (2012)
  192. PDGFA-associated protein 1 is a novel target of c-Myc and contributes to colorectal cancer initiation and progression. Cui HY, Wei W, Qian MR, Tian RF, Fu X, Li HW, Nan G, Yang T, Lin P, Chen X, Zhu YM, Wang B, Sun XX, Dou JH, Jiang JL, Li L, Wang SJ, Chen ZN. Cancer Commun (Lond) 42 750-767 (2022)
  193. Photon-Induced Near-Field Electron Microscopy of Eukaryotic Cells. Kaplan M, Yoo BK, Tang J, Karam TE, Liao B, Majumdar D, Baltimore D, Jensen GJ, Zewail AH. Angew Chem Int Ed Engl 56 11498-11501 (2017)
  194. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells. Chang C, Takayanagi A, Yoshida T, Shimizu N. Exp Cell Res 319 1146-1155 (2013)
  195. Src defines a new pool of EGFR substrates. Michael N, Jura N. Nat Struct Mol Biol 22 945-947 (2015)
  196. Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling. Yin DM, Hannam JS, Schmitz A, Schiemann O, Hagelueken G, Famulok M. Angew Chem Int Ed Engl 56 8417-8421 (2017)
  197. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation. Li M, Yang J, Zhang L, Tu S, Zhou X, Tan Z, Zhou W, He Y, Li Y. J Exp Clin Cancer Res 38 211 (2019)
  198. A regulatory role of membrane by direct modulation of the catalytic kinase domain. Prakash P. Small GTPases 12 246-256 (2021)
  199. Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas. Meseure D, Drak Alsibai K, Vacher S, Hatem R, Nicolas A, Callens C, Lerebours F, Bieche I. Anal Cell Pathol (Amst) 2020 9268236 (2020)
  200. Autophosphorylation of EGFR at Y954 Facilitated Homodimerization and Enhanced Downstream Signals. Thirukkumaran OM, Kluba M, Hofkens J, Mizuno H. Biophys J 119 2127-2137 (2020)
  201. Controlling ERK Activation Dynamics in Mammary Epithelial Cells with Alternating Electric Fields through Microelectrodes. Guo L, Li H, Wang Y, Li Z, Albeck J, Zhao M, Qing Q. Nano Lett 19 7526-7533 (2019)
  202. Cytokine signaling exposed. Hubbard SR. Structure 19 1-2 (2011)
  203. Distinct interactions stabilize EGFR dimers and higher-order oligomers in cell membranes. Mudumbi KC, Burns EA, Schodt DJ, Petrova ZO, Kiyatkin A, Kim LW, Mangiacapre EM, Ortiz-Caraveo I, Rivera Ortiz H, Hu C, Ashtekar KD, Lidke KA, Lidke DS, Lemmon MA. Cell Rep 43 113603 (2024)
  204. research-article EGFs and ERBBs--brief history and prospects. Stern DF. Semin Cell Dev Biol 21 917-921 (2010)
  205. ErbB4 point mutation in CU3 inbred rats affects gonadotropin-releasing-hormone neuronal function via compromised neuregulin-stimulated prostaglandin E2 release from astrocytes. Moeller-Gnangra H, Ernst J, Pfeifer M, Heger S. Glia 67 309-320 (2019)
  206. Inhibitor-Directed Spin Labelling-A High Precision and Minimally Invasive Technique to Study the Conformation of Proteins in Solution. Yin DM, Hammler D, Peter MF, Marx A, Schmitz A, Hagelueken G. Chemistry 24 6665-6671 (2018)
  207. Ligand binding effects on the activation of the EGFR extracellular domain. Shao Q, Zhu W. Phys Chem Chem Phys 21 8141-8151 (2019)
  208. Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state. Wang L, Paudel BB, McKnight RA, Janes KA. Nat Commun 14 2110 (2023)
  209. Role of Cholesterol in Transmembrane Dimerization of the ErbB2 Growth Factor Receptor. Pawar AB, Sengupta D. J Membr Biol 254 301-310 (2021)
  210. Role of the Lipid Environment in the Dimerization of Transmembrane Domains of Glycophorin A. Kuznetsov AS, Volynsky PE, Efremov RG. Acta Naturae 7 122-127 (2015)
  211. Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers. Choi B, Cha M, Eun GS, Lee DH, Lee S, Ehsan M, Chae PS, Heo WD, Park Y, Yoon TY. Elife 9 (2020)
  212. Structural basis of the effect of activating mutations on the EGF receptor. Galdadas I, Carlino L, Ward RA, Hughes SJ, Haider S, Gervasio FL. Elife 10 (2021)
  213. A growth-based platform for detecting domain-peptide interactions in the cytoplasm of mammalian cells. Kimura Y, Kashima D, Kawahara M. Sci Rep 12 18028 (2022)
  214. A premature termination of human epidermal growth factor receptor transcription in Escherichia coli. Elloumi-Mseddi J, Jellali K, Villalobo A, Aifa S. ScientificWorldJournal 2014 830923 (2014)
  215. Allosteric Inhibition of the Epidermal Growth Factor Receptor. Sinclair JKL, Robertson WE, Mozumdar D, Quach K, Schepartz A. Biochemistry 60 500-512 (2021)
  216. An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations. Chakroborty D, Ojala VK, Knittle AM, Drexler J, Tamirat MZ, Ruzicka R, Bosch K, Woertl J, Schmittner S, Elo LL, Johnson MS, Kurppa KJ, Solca F, Elenius K. Cancer Res Commun 2 10-27 (2022)
  217. Basic Amino Acids Within the Juxtamembrane Domain of the Epidermal Growth Factor Receptor Regulate Receptor Dimerization and Auto-phosphorylation. Mohr JD, Wagenknecht-Wiesner A, Holowka DA, Baird BA. Protein J 39 476-486 (2020)
  218. Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents. Bagul C, Rao GK, Veena I, Kulkarni R, Tamboli JR, Akunuri R, Shaik SP, Pal-Bhadra M, Kamal A. Mol Divers (2022)
  219. Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth. Chervo MF, Cordo Russo RI, Petrillo E, Izzo F, De Martino M, Bellora N, Cenciarini ME, Chiauzzi VA, Santa María de la Parra L, Pereyra MG, Güttlein LN, Podhajcer OL, Daniotti JL, Dupont A, Barchuk S, Figurelli S, Lopez Della Vecchia D, Roa JC, Guzmán P, Proietti CJ, Schillaci R, Elizalde PV. Oncogene 39 6245-6262 (2020)
  220. Comparative expression of soluble, active human kinases in specialized bacterial strains. Sunderhaus A, Imran R, Enoh E, Adedeji A, Obafemi T, Abdel Aziz MH. PLoS One 17 e0267226 (2022)
  221. Comprehensive Model for Epidermal Growth Factor Receptor Ligand Binding Involving Conformational States of the Extracellular and the Kinase Domains. Hajdu T, Váradi T, Rebenku I, Kovács T, Szöllösi J, Nagy P. Front Cell Dev Biol 8 776 (2020)
  222. Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights. Carraway KL, Kozloski GA. F1000 Biol Rep 1 72 (2009)
  223. Discrete Coiled Coil Rotamers Form within the EGFRvIII Juxtamembrane Domain. Mozumdar D, Doerner A, Zhang JY, Rafizadeh DN, Schepartz A. Biochemistry 59 3965-3972 (2020)
  224. Disruptin, a cell-penetrating peptide degrader of EGFR: Cell-Penetrating Peptide in Cancer Therapy. Mehta RK, Shukla S, Ramanand SG, Somnay V, Bridges AJ, Lawrence TS, Nyati MK. Transl Oncol 14 101140 (2021)
  225. Dynamics fingerprints of active conformers of epidermal growth factor receptor kinase. Barletta GP, Hasenahuer MA, Fornasari MS, Parisi G, Fernandez-Alberti S. J Comput Chem 39 2472-2480 (2018)
  226. EGFR transactivates RON to drive oncogenic crosstalk. Franco Nitta C, Green EW, Jhamba ED, Keth JM, Ortiz-Caraveo I, Grattan RM, Schodt DJ, Gibson AC, Rajput A, Lidke KA, Wilson BS, Steinkamp MP, Lidke DS. Elife 10 e63678 (2021)
  227. Ebselen oxide and derivatives are new allosteric HER2 inhibitors for HER2-positive cancers. Blasquez L, Bouzinba-Segard H, Bourdoulous S, Faure C. Mol Oncol 17 1981-1999 (2023)
  228. Embryonic lethality and defective mammary gland development of activator-function impaired conditional knock-in Erbb3 V943R mice. Senger K, Yuan W, Sagolla M, Doerr J, Bolon B, Ziai J, Sun KH, Warming S, Roose-Girma M, Zhang N, Tam L, Newman RJ, Chaudhuri S, Antony A, Goldstein LD, Durinck S, Jaiswal BS, Lafkas D, Modrusan Z, Seshagiri S. Adv Genet (Hoboken) 2 e10036 (2021)
  229. Evolution of Functional Diversity in the Holozoan Tyrosine Kinome. Yeung W, Kwon A, Taujale R, Bunn C, Venkat A, Kannan N. Mol Biol Evol 38 5625-5639 (2021)
  230. Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study. Motamedi Z, Rajabi-Maham H, Azimzadeh Irani M. J Mol Model 27 361 (2021)
  231. In the literature: December 2018. Gambardella V, Fleitas T, Cervantes A. ESMO Open 3 e000468 (2018)
  232. In-cell structural dynamics of an EGF receptor during ligand-induced dimer-oligomer transition. Kozer N, Clayton AHA. Eur Biophys J 49 21-37 (2020)
  233. Insider influence on ErbB activity. Shilo BZ. Cell 143 181-182 (2010)
  234. Letter Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator. Anastasi S, Zhu SJ, Ballarò C, Manca S, Lamberti D, Wang LJ, Alemà S, Yun CH, Segatto O. Cell 165 1031-1034 (2016)
  235. Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR. Becker C, Öcal S, Nguyen HD, Phan T, Keul M, Simard JR, Rauh D. Chembiochem 17 990-994 (2016)
  236. Novel insights into the mechanism of cell cycle kinases Mec1(ATR) and Tel1(ATM). Tannous EA, Burgers PM. Crit Rev Biochem Mol Biol 56 441-454 (2021)
  237. Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies. Opo FADM, Moulay M, Zari A, Alqaderi A, Alkarim S, Zari T, Bhuiyan MA, Mahmoud MM, Aljoud F, Suhail M, Edris S, Ramadan WS, Kamal MA, Nemmiche S, Ahammad F. Front Pharmacol 13 1027890 (2022)
  238. Programming cell-surface signaling by phase-separation-controlled compartmentalization. Li R, Li T, Lu G, Cao Z, Chen B, Wang Y, Du J, Li P. Nat Chem Biol 18 1351-1360 (2022)
  239. S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma. Huang W, Zou L, Hao Z, Wang B, Mao F, Duan Q, Guo D. Front Oncol 12 904383 (2022)
  240. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody. Zeronian MR, Doulkeridou S, van Bergen En Henegouwen PMP, Janssen BJC. BMC Mol Cell Biol 23 12 (2022)
  241. TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. Bi J, Wu Z, Zhang X, Zeng T, Dai W, Qiu N, Xu M, Qiao Y, Ke L, Zhao J, Cao X, Lin Q, Chen XL, Xie L, Ouyang Z, Guo J, Zheng L, Ma C, Guo S, Chen K, Mo W, Fu G, Zhao TJ, Wang HR. Nat Commun 14 2342 (2023)
  242. The autoinhibited state of MKK4: Phosphorylation, putative dimerization and R134W mutant studied by molecular dynamics simulations. Shevchenko E, Poso A, Pantsar T. Comput Struct Biotechnol J 18 2687-2698 (2020)
  243. The combined action of the intracellular regions regulates FGFR2 kinase activity. Lin CC, Wieteska L, Poncet-Montange G, Suen KM, Arold ST, Ahmed Z, Ladbury JE. Commun Biol 6 728 (2023)
  244. The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs. Liang LY, Roy M, Horne CR, Sandow JJ, Surudoi M, Dagley LF, Young SN, Dite T, Babon JJ, Janes PW, Patel O, Murphy JM, Lucet IS. Biochem J 478 3351-3371 (2021)
  245. Transmembrane signaling on a protocell: Creation of receptor-enzyme chimeras for immunodetection of specific antibodies and antigens. Su J, Kitaguchi T, Ohmuro-Matsuyama Y, Seah T, Ghadessy FJ, Hoon S, Ueda H. Sci Rep 9 18189 (2019)
  246. Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers. Zhao J, Mohan N, Nussinov R, Ma B, Wu WJ. Antibodies (Basel) 10 (2021)
  247. Two-step release of kinase autoinhibition in discoidin domain receptor 1. Sammon D, Hohenester E, Leitinger B. Proc Natl Acad Sci U S A 117 22051-22060 (2020)
  248. WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models. Conage-Pough JE, Stopka SA, Oh JH, Mladek AC, Burgenske DM, Regan MS, Baquer G, Decker PA, Carlson BL, Bakken KK, Zhang J, Liu L, Sun C, Mu Z, Zhong W, Tran NL, Elmquist WF, Agar NYR, Sarkaria JN, White FM. Neurooncol Adv 5 vdad066 (2023)


Quick links